Abstract
Although a wealth of evidence supports the use of 3-hydroxy-3- methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) in patients with clinically evident coronary artery disease, these agents are still underutilized. Statins are the most effective agents in reducing low-density lipoprotein-cholesterol among lipid-lowering drugs, and studies have recently shown that they improve endothelial function and plaque stabilization, and induce regression of atherosclerotic lesions. This article reviews the most recent evidence and guideline recommendations supporting the use of statins in chronic stable angina pectoris and acute coronary syndromes.
| Original language | English |
|---|---|
| Pages (from-to) | 547-550 |
| Number of pages | 4 |
| Journal | Clinical Cardiology |
| Volume | 27 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 2004 |
Keywords
- Acute coronary syndromes
- Chronic stable angina
- Coronary artery disease
- Statins
Fingerprint
Dive into the research topics of 'Should standard medical therapy for angina include a statin?'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver